Dr. Majeti is Professor of Medicine, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford University School of Medicine. He is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, MD, where he investigated acute myeloid leukemia (AML) stem cells and therapeutic targeting with anti-CD47 antibodies. Dr. Majeti directs an active NIH-funded laboratory that focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly AML, and has published over 100 peer-reviewed articles.
Ravindra Majeti MD, PhD
Board of Trustees of the Leland Stanford Junior University
Palo Alto, California
United States
Project Title
Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells in Human Myeloid Malignancies Personalized Metabolic Targeting of Epigenetic AML Mutations Through the Alpha-Ketoglutarate Pathway
Program
Discovery
Translational Research Program